STAT活化抑制蛋白2基因在前列腺癌中的表达水平及与临床病理特征的关系

doi:10.3969/j.issn.1006-5725.2025.18.009

摘要/Abstract

摘要：

目的探讨STAT活化抑制蛋白2（protein inhibitor of the activated STAT2， PIAS2）基因在前列腺癌中的表达水平及其与临床病理特征的关系，以及PIAS2对前列腺癌脂质代谢重编程的潜在作用。方法采用癌症基因图谱（The Cancer Genome Atlas Program，TCGA）数据库和人类蛋白图谱（Human Protein Atas，HPA）免疫组化分析显示PIAS2蛋白的表达情况；采用qRT-PCR、Western bolt及免疫组化检测前列腺癌组织和周围癌旁组织中PIAS2的表达，并分析其与患者临床病理特征的关系；慢病毒感染前列腺癌细胞株PC-3M，稳定敲低PIAS2，通过超高效液相色谱质谱技术（UPLC-MS）进行脂质组学分析。结果 TCGA分析显示PIAS2在前列腺癌组织的表达高于癌旁组织，HPA免疫组化分析显示PIAS2蛋白在前列腺癌组织高表达；PIAS2 mRNA和蛋白在前列腺癌中的表达量相较于癌旁组织均有显著提升，差异有统计学意义（P < 0.05）；免疫组织化学显示PIAS2蛋白表达主要定位在前列腺的细胞核，且前列腺癌组织的AOD值显著高于癌旁组织：临床病理参数研究结果显示，PIAS2与Gleason评分、TNM分期具有相关性（P < 0.05），而与患者年龄、PSA及淋巴结转移之间相关性无统计学意义（P > 0.05）；UPLC-MS分析提示，敲降PIAS2影响10种脂类变化，与shNC组相比，shPIAS2组的磷脂酰胆碱和磷脂酰乙醇胺的含量下调，磷脂酰肌醇、磷脂酰丝氨酸、二酰基甘油和三酰基甘油的含量上调。结论 PIAS2蛋白的表达量在前列腺癌组织中明显升高，提示PIAS2与前列腺癌的发生发展有关，其发病机制可能与前列腺癌的脂质代谢异常相关。

关键词: 前列腺癌, STAT活化抑制蛋白2, 免疫组织化学, 脂质代谢重编程

Abstract:

Objective To investigate the expression level of the protein inhibitor of the activated STAT2 （PIAS2） gene in prostate cancer and its relationship with clinicopathological features， and the potential role of PIAS2 in reprogramming lipid metabolism in prostate cancer. Methods The Cancer Genome Atlas Program （TCGA） database and HPA immunohistochemical analysis were used to show the expression of PIAS2 protein； qRT-PCR， Western bolt and immunohistochemistry were used to detect PIAS2 in prostate cancer tissues and their paracancerous tissues. PIAS2 expression in prostate cancer tissues and its paracancerous tissues and analyzed its relationship with clinicopathological features of patients； lentivirus infected prostate cancer cell line PC-3M， which stably knocked down PIAS2， was analyzed by ultra performance liquid chromatography mass spectrometry （UPLC-MS） for lipidomics. Results TCGA analysis showed that the expression of PIAS2 in prostate cancer tissues was higher than that in paracancerous tissues， and HPA immunohistochemistry analysis showed that PIAS2 protein was highly expressed in prostate cancer tissues； the expression of PIAS2 mRNA and protein was significantly elevated in prostate cancer compared with that in paracancerous tissues， and the difference was statistically significant （P < 0.05）； immunohistochemistry showed that PIAS2 protein Expression of PIAS2 protein was mainly localized in the nucleus of prostate， and the AOD value of prostate cancer tissues was significantly higher than that of paraneoplastic tissues： the results of clinicopathological parameters showed that PIAS2 had correlation with Gleason score and TNM stage （P < 0.05）， while there was no statistically significant correlation with the age of the patients， PSA and lymph node metastasis； UPLC-MS analysis suggested that the knockdown of PIAS2 affected 10 lipid changes， with down-regulation of phosphatidylcholine and phosphatidylethanolamine and up-regulation of phosphatidylinositol， phosphatidylserine， diacylglycerol， and triacylglycerol in the shPIAS2 group compared with the shNC group. Conclusions The expression of PIAS2 protein was significantly elevated in prostate cancer tissues， suggesting that PIAS2 is associated with the development of prostate cancer， and its pathogenesis may be related to the abnormal lipid metabolism of prostate cancer.

Key words: prostate cancer, STAT activation inhibitory protein 2, immunohistochemistry, lipid metabolism reprogramming

中图分类号:

R737.25

李唯尊,邢晨,安恒庆. STAT活化抑制蛋白2基因在前列腺癌中的表达水平及与临床病理特征的关系[J]. 实用医学杂志, 2025, 41(18): 2844-2852.

Weizun LI,Chen XING,Hengqing AN. STAT activation inhibitory protein 2 is involved in reprogramming of lipid metabolism by regulating the prostate cancer development[J]. The Journal of Practical Medicine, 2025, 41(18): 2844-2852.

图/表 7

表1

图1

图2

表2

图3

图4

图5

参考文献 30

[1]	CAO W， CHEN H D， YU Y W， et al. Changing profiles of cancer burden worldwide and in China： A secondary analysis of the global cancer statistics 2020［J］. Chin Med J （Engl）， 2021， 134（7）： 783-791. doi:10.1097/cm9.0000000000001474 doi: 10.1097/cm9.0000000000001474
[2]	LI X， RASUL A， SHARIF F， et al. PIAS family in cancer： From basic mechanisms to clinical applications［J］. Front Oncol， 2024， 14： 1376633. doi:10.3389/fonc.2024.1376633 doi: 10.3389/fonc.2024.1376633
[3]	GHAFOURI-FARD S， HUSSEN B M， NICKNAFS F， et al. Expression Analysis of Protein Inhibitor of Activated STAT in Inflammatory Demyelinating Polyradiculoneuropathy［J］. Front Immunol， 2021， 12：659038. doi:10.3389/fimmu.2021.659038 doi: 10.3389/fimmu.2021.659038
[4]	MAGALHAES J， TRESSE E， EJLERSKOV P， et al. PIAS2-mediated blockade of IFN-β signaling： A basis for sporadic Parkinson disease dementia［J］.Mol Psychiatry， 2021， 26（10）： 6083-6099. doi:10.1038/s41380-021-01207-w doi: 10.1038/s41380-021-01207-w
[5]	LI C， BOUTET A， PASCARIU C M， et al. SUMO Proteomics Analyses Identify Protein Inhibitor of Activated STAT-Mediated Regulatory Networks Involved in Cell Cycle and Cell Proliferation［J］. J Proteome Res， 2023， 22（3）： 812-825. doi:10.1021/acs.jproteome.2c00557 doi: 10.1021/acs.jproteome.2c00557
[6]	KUKKULA A， OJALA V K， MENDEZ L M， et al. Therapeutic Potential of Targeting the SUMO Pathway in Cancer［J］. Cancers （Basel）， 2021， 13（17）：4402. doi:10.3390/cancers13174402 doi: 10.3390/cancers13174402
[7]	RODRIGUES J S， CHENLO M， BRAVO S B， et al. dsRNAi-mediated silencing of PIAS2beta specifically kills anaplastic carcinomas by mitotic catastrophe［J］. Nat Commun， 2024， 15（1）： 3736. doi:10.1038/s41467-024-50135-0 doi: 10.1038/s41467-024-50135-0
[8]	LIANG J， LI L， LI L， et al. Lipid metabolism reprogramming in head and neck cancer［J］. Front Oncol， 2023， 13： 1271505. doi:10.3389/fonc.2023.1271505 doi: 10.3389/fonc.2023.1271505
[9]	TANG M， LI X， REN J， et al. Limosilactobacillus reuteri HM108 alleviates obesity in rats fed a high-fat diet by modulating the gut microbiota， metabolites， and inhibiting the JAK-STAT signalling pathway［J］. Front Nutr， 2025， 12：1597334. doi:10.3389/fnut.2025.1597334 doi: 10.3389/fnut.2025.1597334
[10]	KONG X， CHEN H， LI D， et al. Effects of imbalance of lipid metabolism through NF-κB pathway on atherosclerosis and vascular aging in rats［J］. Cell Mol Biol （Noisy-le-grand）， 2022， 67（5）： 144-150. doi:10.14715/cmb/2021.67.5.20 doi: 10.14715/cmb/2021.67.5.20
[11]	杨剑波，邵继春，曾治军，等. lncRNA MIF-AS1调节miR-423-5p/PYCR1轴对前列腺癌细胞恶性生物学行为的影响［J］. 实用医学杂志， 2024， 40（18）： 2544-2549.
[12]	SHU H， CHEN X， ZHAO J， et al. PIAS family gene expression： Implications for prognosis， immunomodulation， and chemotherapy response［J］. Am J Transl Res， 2024， 16（11）： 6346-6364. doi:10.62347/jrdp4018 doi: 10.62347/jrdp4018
[13]	PENG Y， LEE J， ZHU C， et al. A novel role for protein inhibitor of activated STAT （PIAS） proteins in modulating the activity of Zimp7， a novel PIAS-like protein， in androgen receptor-mediated transcription［J］. J Biol Chem， 2010， 285（15）： 11465-11475. doi:10.1074/jbc.m109.079327 doi: 10.1074/jbc.m109.079327
[14]	杨锐，易成，陈钢鑫，等. PIAS2蛋白和生精细胞凋亡在无精子症中相关性的研究［J］. 中国优生与遗传杂志， 2022， 30（7）： 1177-1181.
[15]	DU J， DU Y， CHEN L， et al. IL-17 promotes melanoma through TRAF2 as a scaffold protein recruiting PIAS2 and ELAVL1 to induce EPHA5［J］. Biochim Biophys Acta Mol Cell Res， 2023， 1870（7）： 119547. doi:10.1016/j.bbamcr.2023.119547 doi: 10.1016/j.bbamcr.2023.119547
[16]	LI Y， LIN H， SHU S， et al. Integrative transcriptome analysis reveals TEKT2 and PIAS2 involvement in diabetic nephropathy［J］. FASEB J，2022，36（11）：e22592. doi:10.1096/fj.202200740rr doi: 10.1096/fj.202200740rr
[17]	WADA H， SUZUKI D， NIIKURA T. Regulation of ALS-Associated SOD1 Mutant SUMOylation and Aggregation by SENP and PIAS Family Proteins［J］. J Mol Neurosci，2020，70（12）：2007-2014. doi:10.1007/s12031-020-01604-w doi: 10.1007/s12031-020-01604-w
[18]	GHAFOURI-FARD S， HESAMI O， NAZER N， et al. Expression of PIAS Genes in Migraine Patients［J］. J Mol Neurosci， 2021， 71（10）： 2053-2059. doi:10.1007/s12031-021-01834-6 doi: 10.1007/s12031-021-01834-6
[19]	LIU Y， LIAO S， BENNETT S， et al. STAT3 and its targeting inhibitors in osteosarcoma［J］.Cell Prolif， 2021， 54（2）： e12974. doi:10.1111/cpr.12974 doi: 10.1111/cpr.12974
[20]	MOHAN C D， RANGAPPA S， NAYAK S C， et al. Paradoxical functions of long noncoding RNAs in modulating STAT3 signaling pathway in hepatocellular carcinoma［J］. Biochim Biophys Acta Rev Cancer， 2021， 1876（1）： 188574. doi:10.1016/j.bbcan.2021.188574 doi: 10.1016/j.bbcan.2021.188574
[21]	WU R， FANG J， LIU M， et al. SUMOylation of the transcription factor ZFHX3 at Lys-2806 requires SAE1， UBC9， and PIAS2 and enhances its stability and function in cell proliferation［J］.J Biol Chem，2020， 295（19）：6741-6753. doi:10.1074/jbc.ra119.012338 doi: 10.1074/jbc.ra119.012338
[22]	CHEN S Y， CHIANG C F， SU Y F， et al. Protein inhibitor of activated signal transducer and activator of transcription 2 is an oncoprotein in oral squamous cell carcinoma and related to cigarette smoking - An in vitro study［J］. J Dent Sci， 2024， 19（4）： 1983-1990. doi:10.1016/j.jds.2024.07.013 doi: 10.1016/j.jds.2024.07.013
[23]	PENNEY K L， TYEKUCHEVA S， ROSENTHAL J， et al. Metabolomics of Prostate Cancer Gleason Score in Tumor Tissue and Serum［J］.Mol Cancer Res， 2021， 19（3）： 475-484. doi:10.1158/1541-7786.mcr-20-0548 doi: 10.1158/1541-7786.mcr-20-0548
[24]	徐焕铭. CRNDE调控PIAS2介导急性髓细胞白血病预后调节机制的研究［D］. 沈阳：中国医科大学， 2021.
[25]	贾雯茜. STAT3介导苏氨酸调控HepG2细胞甘油三酯沉积［D］. 扬州：扬州大学， 2024.
[26]	YANG M， WU S， CAI W， et al. Hypoxia-induced MIF induces dysregulation of lipid metabolism in Hep2 laryngocarcinoma through the IL-6/JAK-STAT pathway［J］.Lipids Health Dis， 2022，21（1）： 82. doi:10.1186/s12944-022-01693-z doi: 10.1186/s12944-022-01693-z
[27]	STOICA C， FERREIRA A K， HANNAN K， et al. Bilayer forming phospholipids as targets for cancer therapy［J］. Int J Mol Sci， 2022， 23（9）： 5266. doi:10.3390/ijms23095266 doi: 10.3390/ijms23095266
[28]	LIU Q， ZHANG X， QI J， et al. Comprehensive profiling of lipid metabolic reprogramming expands precision medicine for HCC［J］. Hepatology， 2025， 81（4）： 1164-1180. doi:10.1097/hep.0000000000000962 doi: 10.1097/hep.0000000000000962
[29]	LI X， NAKAYAMA K， GOTO T， et al. High level of phosphatidylcholines/lysophosphatidylcholine ratio in urine is associated with prostate cancer［J］. Cancer Sci， 2021， 112（10）： 4292-4302. doi:10.1111/cas.15093 doi: 10.1111/cas.15093
[30]	GUAN Y， CHEN X， WU M， et al. The phosphatidylethanolamine biosynthesis pathway provides a new target for cancer chemotherapy［J］. J Hepatol， 2020， 72（4）： 746-760. doi:10.1016/j.jhep.2019.11.007 doi: 10.1016/j.jhep.2019.11.007

实验材料	购买平台
胎牛血清	上海瑞博赛生物科技有限公司
RPMI-1640培养基	美国海克隆公司
双抗、胰酶	上海碧云天生物科技有限公司
SDS-PAGE凝胶制备试剂盒、BCA蛋白定量试剂盒、蛋白取样缓冲液	北京索莱宝公司
PCR相关试剂盒	中国北京Takara公司
Trizol RNA提取试剂	美国Invitrogen公司
GAPDH单克隆抗体	英国Abcam公司
PIAS2多克隆抗体	中国Abclonal公司
PBS、过氧化氢、通用二抗	中国中杉金桥公司
PIAS2和GAPDH引物	上海生工生物技术有限公司